The price of the British laboratory, which had embarked on the battle of Covid with the University of Oxford, has quadrupled in ten years.
“Ten years ago, we started almost from zero in cancer. Today, we have taken the leadership in several markets including China. We give ourselves four to five years to become the world number one.In Chicago, at the World Cancer Congress, Frenchman Pascal Soriot, who took over the reins of AstraZeneca in 2012, relishes the progress made.
Read alsoCancer: the great battle of the pharmaceutical giants
The results of the British laboratory were among the most anticipated, in particular its progress in a variant of metastatic breast cancer (Her2-low), which affects around 50% of patients with this cancer. This would be an additional indication for its young drug Enhertu ($17 million in sales in 2021), developed with its Japanese partner, Daiichi Sankyo. Some analysts estimate that its sales potential could now reach 10 to 15 billion. AstraZeneca would mark an important point on its rival, Roche, whose Herceptin does not work against this variant…
This article is for subscribers only. You have 80% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
Already subscribed? Login